Skip to main content

Table 2 Results of virological and genotypic resistance testing by cohort

From: Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda

  Cohort M12 Cohort M24
HIV RNA ≥ 1,000 copies/ml (%) 25 50
Available genotypic resistance (%) 20 (80.0) 42 (84.0)
Wild-type virus (%) 6 (30.0) 10 (23.8)
Resistance to ≥ 1 ARV drug (%) 14 (70.0) 32 (76.2)
Resistance to EFV and NVP (%) 3 (15.0) 1 (2.4)
Resistance to 3TC, EFV, and NVP (%) 9 (45.0) 22 (52.4)
Extensive resistance* (%) 2 (10.0) 9 (21.4)
  1. ARV, antiretroviral; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine
  2. *Resistance to EFV, NVP, 3TC, stavudine, zidovudine, or tenofovir, and didanosine, or multidrug resistance.